The South African government says it could fill the potential gap in the number of doses it will need of the twice-yearly HIV-prevention jab to end Aids by 2043, by getting a group of local pharmaceutical companies to make generic shots from 2027 onwards. There is, however, a hitch. None of the companies that will be involved have a licence from lenacapavir’s inventor, Gilead Sciences, to make the jab.